Costa Rica Law 10113 Implementation: Regulatory Compliance and Export Standards
An analysis of the current state of Law 10113 implementation in Costa Rica, focusing on the harmonization with EU-GMP standards, international traceability requirements, and the transition toward pharmaceutical-grade formulations.
The full implementation of Law 10113 in Costa Rica has transitioned from a theoretical legislative framework to a functional operational environment. For compliance officers and market access teams, the current landscape requires a dual focus: strict adherence to the national traceability requirements and the alignment of local production with international export standards, specifically EU-GMP Annex 1 and Annex 15. The Ministry of Health (Ministerio de Salud) and the Ministry of Agriculture (MAG) have stabilized the licensing process, but the challenge now lies in maintaining the integrity of the secondary supply chain, where medical-grade standards must survive the transition from cultivation to the pharmacy shelf.
Harmonization with EU-GMP Standards
For operators in Costa Rica aiming for the European market, the domestic regulatory baseline is merely the starting point. Law 10113 provides the legal scaffolding, but international market access depends on the continuous validation of processes. We are observing an increasing emphasis on Annex 1 (Manufacture of Sterile Medicinal Products) principles, even for non-sterile herbal materials, to mitigate the risks of cross-contamination and microbial growth.
Quality Management Systems (QMS) must now move beyond simple documentation of agricultural practices (GACP) and integrate deep pharmaceutical quality oversight. This involves the rigorous qualification of equipment and the validation of cleaning processes to ensure that active pharmaceutical ingredients (APIs) maintain stability throughout their shelf life. For compliance teams, this means that every batch must not only meet the potency requirements established by the national laboratory but also demonstrate a clear audit trail that satisfies a potential EMA inspection.
Traceability and the Control of Restricted Substances
A critical pillar of the current implementation phase is the digital integration with the International Narcotics Control Board (INCB) guidelines for reporting. Costa Rica has adopted a robust tracking system that monitors the movement of "controlled substances" from the seed stage through to the final dispensing. Regulatory officers must ensure that internal Enterprise Resource Planning (ERP) systems are fully synchronized with the state-mandated platform.
The implications of a data mismatch are significant, potentially leading to the suspension of export permits or administrative sanctions. In this context, the role of the Qualified Person (QP) or Technical Director (Regente) has evolved. They are no longer just signatories but active monitors of real-time data. The focus is on preventing diversion while ensuring that the "Chain of Custody" remains unbroken, a requirement that is particularly scrutinized during the transport and logistics phase involving international boundaries.
Market Access and Emerging Formulations
As we enter 2026, the regulatory conversation has shifted from raw flower to advanced pharmaceutical formulations. The Ministry of Health’s current stance encourages the registration of standardized extracts and finished dosage forms, such as oils and capsules, which offer more predictable pharmacokinetic profiles. For market access teams, the priority is the submission of comprehensive stability data and certificates of analysis (CoA) that reflect these rigorous standards.
The stabilization of Law 10113 has also paved the way for more refined insurance coverage discussions within the domestic healthcare sector. However, for a product to be considered for large-scale procurement or reimbursement, it must possess a "Product Dossier" that rivals conventional pharmaceuticals. This necessitates a transition from "botanical thinking" to "pharmaceutical precision," where every variable in the cultivation and extraction process is treated as a critical process parameter (CPP) that can influence the final therapeutic outcome. Compliance is no longer a hurdle to be cleared once; it is a permanent state of operational readiness.
Tags
